https://www.selleckchem.com/products/AZD0530.html
CBiPES 10 mg/kg reduced global dyskinesia by 60% (P less then 0.0001), while peak dose dyskinesia was reduced by 66% (P less then 0.001), compared to L-DOPA/vehicle. CBiPES 10 mg/kg also diminished global PLBs by 56% (P less then 0.0001), while peak dose PLBs were reduced by 64% (P less then 0.001), compared to L-DOPA/vehicle. Lastly, CBiPES enhanced the anti-parkinsonian action of L-DOPA, by reducing global parkinsonian disability by 43% (P less then 0.01), compared to L-DOPA/vehicle. Our results provide further evidence that
Like
Comment
Share
